Value
4.5/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 7.5 |
XNCR · Why this verdict
Why Xencor (XNCR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.1/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Xencor combines a 90% gap to analyst targets and a 3-of-4 earnings beat streak with clear value-trap warning signs — a 22.6% revenue decline, margin compression, and negative free cash flow — in a binary biotech setup with elevated short interest (22%).
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analyst price targets imply 90% upside for Xencor, reflecting significant expected value in its pipeline. Sentiment breakdown | Analyst upside should stay above 50% over the next 12 months if the case remains intact. | ↑Improving |
| CounterA 90% upside estimate for a clinical-stage biotech can be driven by binary trial-outcome assumptions that may not play out as modeled. | ||
The engine classifies Xencor as speculative given its status as a binary biotech industry name, where single trial or regulatory events can drive large price swings. Suitability rationale | The stock should avoid a single-event price swing of more than 30% over the next 12 months if binary risk stays contained. | →Stable |
| CounterBinary risk is inherent to clinical-stage biotech investing and cannot be diversified away at the single-stock level regardless of other fundamentals. | ||
The engine flags 3 of 5 value-trap signals for Xencor: declining revenue of -22.6% YoY, operating margin compression to -3.9%, and negative free cash flow. Bear case | Revenue growth should turn positive within 2-3 quarters if the decline is a temporary licensing-revenue timing issue rather than a structural problem. | ↑Improving |
| CounterClinical-stage and royalty-dependent biotechs often show lumpy, milestone-driven revenue that can swing sharply without reflecting the underlying pipeline value. | ||
Xencor has beaten consensus estimates in 3 of its last 4 reported quarters, a strong earnings track record despite the revenue-decline concerns. Catalyst breakdown | The company should beat or meet estimates in at least 2 of the next 4 quarters if the earnings track record continues. | ↑Improving |
| CounterBeats for a royalty-dependent biotech can be driven by one-time milestone payments rather than a repeatable operating pattern. | ||
Xencor carries high short interest of 22% of float and an elevated put/call ratio of 1.40, signaling meaningful bearish positioning. Key risks | Short interest should decline below 15% of float over the next quarter if bearish positioning is set to unwind. | ↑Improving |
| CounterHigh short interest in a binary biotech name can also set up a short squeeze on positive trial news, working against the bearish read. | ||
Analyst price targets imply 90% upside for Xencor, reflecting significant expected value in its pipeline.
↑ImprovingSentiment breakdown
- Expectation
- Analyst upside should stay above 50% over the next 12 months if the case remains intact.
CounterA 90% upside estimate for a clinical-stage biotech can be driven by binary trial-outcome assumptions that may not play out as modeled.
The engine classifies Xencor as speculative given its status as a binary biotech industry name, where single trial or regulatory events can drive large price swings.
→StableSuitability rationale
- Expectation
- The stock should avoid a single-event price swing of more than 30% over the next 12 months if binary risk stays contained.
CounterBinary risk is inherent to clinical-stage biotech investing and cannot be diversified away at the single-stock level regardless of other fundamentals.
The engine flags 3 of 5 value-trap signals for Xencor: declining revenue of -22.6% YoY, operating margin compression to -3.9%, and negative free cash flow.
↑ImprovingBear case
- Expectation
- Revenue growth should turn positive within 2-3 quarters if the decline is a temporary licensing-revenue timing issue rather than a structural problem.
CounterClinical-stage and royalty-dependent biotechs often show lumpy, milestone-driven revenue that can swing sharply without reflecting the underlying pipeline value.
Xencor has beaten consensus estimates in 3 of its last 4 reported quarters, a strong earnings track record despite the revenue-decline concerns.
↑ImprovingCatalyst breakdown
- Expectation
- The company should beat or meet estimates in at least 2 of the next 4 quarters if the earnings track record continues.
CounterBeats for a royalty-dependent biotech can be driven by one-time milestone payments rather than a repeatable operating pattern.
Xencor carries high short interest of 22% of float and an elevated put/call ratio of 1.40, signaling meaningful bearish positioning.
↑ImprovingKey risks
- Expectation
- Short interest should decline below 15% of float over the next quarter if bearish positioning is set to unwind.
CounterHigh short interest in a binary biotech name can also set up a short squeeze on positive trial news, working against the bearish read.
Per-dimension breakdown
Quality
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Op margin | 0.0 |
| Current ratio | 6.6 |
| FCF quality | 0.0 |
| Moat | 5.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -90% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
6.9/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 6.9 |
Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 72)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.5 |
| Analyst rating | 8.4 |
| Price target | 8.8 |
- ▸LLM news sentiment: +0.49 (n=5)
- ▸Analyst upside: 33%
Insider
5.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.9 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.8 |
| quality rank | 2.6 |
| growth rank | 4.8 |
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 2.8 |
| 52w position | 8.0 |
Risk (lower is worse)
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.2 |
| days to cover | 2.1 |
| volatility | 0.0 |
| put call | 9.3 |
| implied vol | 0.0 |
| beta | 7.6 |
| debt equity | 8.6 |
| news risk | 5.5 |
- ▸High short interest justified: 23%
- ▸High IV: 91%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
- ▸Earnings in 6 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:6.7>=5.5
- INSIDER:OK
- NEWS_BOOST:ANALYST:0.70
- NEWS_BOOST:ANALYST_CLUSTER(3)
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:1.0<1.5@spot
- EARNINGS_PROXIMITY:6d<=7d
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.04
Upside
+15.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the ASYMMETRY gate's 1.0<1.5@spot outcome against Sentiment at 8.2 and asymmetric R:R of 1.04.
The strongest dimensions are Sentiment at 8.2, Growth at 6.9, and Catalyst at 6.9; the weakest are Quality at 2.3, Peer rank at 3.2, and Technical at 3.6. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 1.04 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Value Trap Revenue Decline Signals
Trip ifRevenue growth turns positive and exceeds 0% YoY, reversing the current -22.6% decline.
- P2Large Analyst Upside Gap
Trip ifAnalyst upside compresses below 30% from the current 90%, undermining the analyst-upside case.
- P3Strong Earnings Beat Streak
Trip ifThe beat streak drops to 1 or fewer of the last 4 quarters, down from the current 3 of 4.
- P4Binary Biotech Speculative Risk
Trip ifThe stock swings by more than 50% around a single binary catalyst event, confirming the binary-biotech risk.
- P5Elevated Short Interest Hedging Pressure
Trip ifShort interest falls below 10% of float from the current 22%, easing the elevated-hedging pressure.